On the heels of the US FDA accepting its non-small-cell lung cancer drug application, Adventrx Pharmaceuticals plans to raise $22.5 million through the sale of 8.2 million units at $2.75 per unit in a registered direct offering to RA Capital Management.
Each unit consists of one share of common stock, a Series A warrant